BR112022008908A2 - Sistemas de permanência gástrica para administração de agentes ativos - Google Patents

Sistemas de permanência gástrica para administração de agentes ativos

Info

Publication number
BR112022008908A2
BR112022008908A2 BR112022008908A BR112022008908A BR112022008908A2 BR 112022008908 A2 BR112022008908 A2 BR 112022008908A2 BR 112022008908 A BR112022008908 A BR 112022008908A BR 112022008908 A BR112022008908 A BR 112022008908A BR 112022008908 A2 BR112022008908 A2 BR 112022008908A2
Authority
BR
Brazil
Prior art keywords
gastric
systems
disclosed
permanence
active agents
Prior art date
Application number
BR112022008908A
Other languages
English (en)
Inventor
KANASTY Rosemary
GRANT Tyler
Altreuter David
Weight Alisha
Moorthy Saumya
Tai Tammy
Jaramillo Montezco Juan
Schwarz Marlene
Hoon Yang Jung
TRAN Jeanne
Duan Michelle
Jing Jie
C Dufour David
Robert Waldemar Ryde Erik
Bhise Nupura
Holar Sonia
De La Torre Nicholas
Simses Craig
Beguin Estelle
Lai Erica
Peeke Erick
Original Assignee
Lyndra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyndra Therapeutics Inc filed Critical Lyndra Therapeutics Inc
Publication of BR112022008908A2 publication Critical patent/BR112022008908A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SISTEMAS DE PERMANÊNCIA GÁSTRICA PARA ADMINISTRAÇÃO DE AGENTES ATIVOS. Sistemas de residência gástrica para administração de agentes, tais como drogas, são divulgados. São divulgadas características que aumentam a retenção gástrica durante o tempo de residência desejado e que permitem um controle mais preciso sobre o tempo de residência, incluindo filamentos circunferenciais que conectam os braços de um sistema de residência gástrico estrelado; braços flexíveis para sistema de residência gástrica; matrizes de desintegração entérica e dependentes do tempo melhoradas (ligantes); e revestimentos poliméricos moduladores da taxa de liberação que são resistentes à mudança nas propriedades da taxa de liberação durante a montagem assistida por calor ou ciclo térmico. Combinações dessas características também são divulgadas.
BR112022008908A 2019-11-08 2020-11-06 Sistemas de permanência gástrica para administração de agentes ativos BR112022008908A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962933313P 2019-11-08 2019-11-08
US201962933211P 2019-11-08 2019-11-08
US201962933348P 2019-11-08 2019-11-08
US201962933210P 2019-11-08 2019-11-08
US201962933226P 2019-11-08 2019-11-08
US202062992075P 2020-03-19 2020-03-19
US202063052905P 2020-07-16 2020-07-16
PCT/US2020/059541 WO2021092491A1 (en) 2019-11-08 2020-11-06 Gastric residence systems for administration of active agents

Publications (1)

Publication Number Publication Date
BR112022008908A2 true BR112022008908A2 (pt) 2022-10-11

Family

ID=75849597

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008908A BR112022008908A2 (pt) 2019-11-08 2020-11-06 Sistemas de permanência gástrica para administração de agentes ativos

Country Status (10)

Country Link
US (1) US20220387311A1 (pt)
EP (1) EP4054545A4 (pt)
JP (1) JP2022553862A (pt)
CN (1) CN115003335A (pt)
AU (1) AU2020378438A1 (pt)
BR (1) BR112022008908A2 (pt)
CA (1) CA3160665A1 (pt)
IL (1) IL292849A (pt)
MX (1) MX2022005494A (pt)
WO (1) WO2021092491A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3173792A1 (en) * 2021-01-19 2022-07-28 Rosemary KANASTY Gastric residence systems for administration of risperidone

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1984009B1 (en) * 2006-01-18 2012-10-24 Qps, Llc Pharmaceutical compositions with enhanced stability
US9062141B2 (en) * 2010-08-06 2015-06-23 Endoshape, Inc. Radiopaque shape memory polymers for medical devices
AU2016342374B2 (en) * 2015-10-23 2022-08-04 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
KR20180090881A (ko) * 2015-12-08 2018-08-13 린드라 인코퍼레이티드 위 체류 시스템을 위한 기하 구성형태
AU2017268840B2 (en) * 2016-05-27 2022-02-10 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
AU2017336154B2 (en) * 2016-09-30 2023-11-09 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
WO2018227147A1 (en) * 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
WO2019060458A1 (en) * 2017-09-20 2019-03-28 Lyndra, Inc. ENCAPSULATION OF GASTRIC SYSTEMS

Also Published As

Publication number Publication date
IL292849A (en) 2022-07-01
AU2020378438A1 (en) 2022-06-02
WO2021092491A1 (en) 2021-05-14
US20220387311A1 (en) 2022-12-08
CN115003335A (zh) 2022-09-02
EP4054545A1 (en) 2022-09-14
JP2022553862A (ja) 2022-12-26
MX2022005494A (es) 2022-08-11
EP4054545A4 (en) 2024-02-14
CA3160665A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
BR112022008908A2 (pt) Sistemas de permanência gástrica para administração de agentes ativos
BR112018003882A2 (pt) material auxiliar para proporcionar eluição de fármaco de vasos
BR112018071699A2 (pt) sistema de liberação médica
BR112022002683A2 (pt) Agonistas não peptídicos do receptor de somatostatina tipo 5 e seus usos
BR112016024764A2 (pt) cateter dotado de porta ou encaixe luer fêmea com septo antimicrobiano
BR112018003845A2 (pt) auxiliares cirúrgicos com medicamentos afetados por materiais ativadores
BR0312445A (pt) Sistemas multiunitários para disponibilização de fármaco de liberação modificada
BR112012009185A2 (pt) realimentação e controle de dose de sistemas de descontaminação distribuída
CO2021006308A2 (es) Proteínas f de prefusión del vrs estabilizadas
BR122012017386B8 (pt) sistema de diálise
BR112017016342A2 (pt) entrega de partículas de agentes ativos hidrofóbicos
BR112018002399A2 (pt) nucleosídeos de pirrolopirimidina e análogos dos mesmos, úteis como agentes antivirais
DK1121099T3 (da) I maven hvilende farmaceutiske præparater til kontrolleret frigivelse
AU2019301069A8 (en) Mixing/administration system for vaccines and medicaments
BR112019015904A2 (pt) Sistemas e métodos para a fabricação de comprimidos, incluindo comprimidos farmacêuticos
EA201890436A1 (ru) Жидкая полимерная система доставки для длительного введения лекарственных средств
AR116501A1 (es) Sistema de suministro de polímero líquido para administración extendida de drogas
BR112018072883A2 (pt) sistema de liberação de fármaco para a liberação de agentes antivirais
BR112022005657A2 (pt) Dispositivo de distribuição de fármaco
PE20160534A1 (es) Sistema de administracion intrauterina
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
MX2018011799A (es) Formas de dosificacion de liberacion prolongada disuasivas de abuso.
CO2024005250A2 (es) Formulaciones y sistemas de erdafitinib para administración intravesical
BR112018010052A2 (pt) peptídeos com propriedades antiangiogênicas, antilinfangiogênicas e antiedêmicas e formulações de nanopartícula
BR112021020421A2 (pt) Composições e métodos para administração de componentes terapêuticos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]